Source comparison
Tesamorelin Work: Storage, Administration & Clinical Considerations Comparison
Mechanism GHRH receptor agonist—stimulates endogenous pituitary GH secretion Direct replacement—exogenous GH injection Tesamorelin preserves natural feedback loops; rhGH bypasses pituitary and suppresses endogenous production Dosing Frequency 2mg daily subcuta
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist—stimulates endogenous pituitary GH secretion
- Direct replacement—exogenous GH injection
- Tesamorelin preserves natural feedback loops; rhGH bypasses pituitary and suppresses endogenous production
- Dosing Frequency
- 2mg daily subcutaneous injection
- 0.15–1.5mg daily subcutaneous injection
- Both require daily administration; compliance equally challenging
- GH Secretion Pattern
- Pulsatile—replicates physiological secretory bursts
- Sustained elevation for 8–12 hours post-injection
- Pulsatile pattern reduces receptor downregulation and metabolic side effects
- Pituitary Suppression
- None—enhances existing secretory capacity
- Marked suppression within 2–4 weeks; recovery takes 8–16 weeks after cessation
- Tesamorelin allows immediate cessation without rebound; rhGH requires tapering
- Glucose Intolerance Risk
- Transient elevations in 7%; HbA1c stable at 26 weeks
- Overt diabetes in 10–15%; sustained insulin resistance common
- Pulsatile GH exposure allows insulin sensitivity recovery between pulses
- VAT Reduction (26 weeks)
- 15.2% mean reduction from baseline
- 10–14% reduction (variable across studies)
- Comparable efficacy; tesamorelin shows slight edge in HIV lipodystrophy trials
- Subcutaneous Fat Effect
- No significant change (−1.8%)
- Variable; some studies show modest reduction
- Tesamorelin's selectivity for VAT is more pronounced
- Fluid Retention/Edema
- 4% incidence
- 15–18% incidence
- Lower with tesamorelin due to preserved GH pulsatility
- Arthralgia/Joint Pain
- 8% incidence
- 22–28% incidence
- Significantly lower with tesamorelin
- Cost (Approximate)
- $3,500–$5,000/month retail
- $1,200–$4,000/month depending on dose
- Tesamorelin is more expensive; cost-benefit depends on side effect profile tolerance
- Storage Requirement
- −20°C unreconstituted; 2–8°C post-reconstitution for ≤48 hours
- 2–8°C; stable for 14–28 days post-reconstitution
- Tesamorelin requires stricter cold chain; less forgiving of temperature excursions
- Bottom Line
- Preferred for patients prioritizing endogenous preservation, lower side effect burden, and selective VAT reduction—best for metabolic rather than anabolic goals
- Preferred for GH deficiency replacement or when higher IGF-1 elevation is desired—requires closer metabolic monitoring